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A series of chroman derivatives previously reported as potassium channel openers, as well as some
newly synthesized simpliﬁed structures, were examined for their in vitro effects on the growth of three
human high-grade glioma cell lines: U373, T98G, and Hs683. Signiﬁcant in vitro growth inhibitory
activity was observed with 2,2-dimethylchroman-type nitro-substituted phenylthioureas, such as
compounds 4o and 4p. Interestingly, most tested phenylureas were found to be slightly less active, but
more cell selective (normal versus tumor glial cells, such as 3d, 3e, and 3g), thus less toxic, than the
corresponding phenylthioureas. No signiﬁcant differences were observed in terms of chroman-
derivative-induced growth inhibitory effects between glioma cells sensitive to pro-apoptotic stimuli
(Hs683 glioma cells) and glioma cells associated with various levels of resistance to pro-apoptotic stimuli
(U373 and T98G glioma cells), a feature that suggests non-apoptotic-mediated growth inhibition. Flow
cytometry analyses conﬁrmed the absence of pro-apoptotic effects for phenylthioureas and phenylureas
when analyzed in U373 glioma cells and demonstrated U373 cell cycle arrest in the G0/G1 phase.
Computer-assisted phase-contrast videomicroscopy revealed that 3d and 3g displayed cytostatic effects,
while 3e displayed cytotoxic ones. As a result, this work identiﬁed phenylurea-type 2,2-
dimethylchromans as a new class of antitumor agents to be further explored for an innovative thera-
peutic approach for high-grade glioma and/or for a possible new mechanism of action.
 2012 Elsevier Masson SAS. All rights reserved.1. Introduction
High-grade (anaplastic astrocytoma and glioblastoma (GBM))
glioma patients are associated with dismal prognoses because of:
(i) the marked diffuse invasion of glioma cells into the braine triphosphate; SUR, sulfo-





son SAS. All rights reserved.parenchyma [1,2], rendering elusive complete surgical resection
[3], and (ii) the intrinsic resistance of glioma cells to pro-apoptotic
stimuli [2], thus to conventional radiotherapy and chemotherapy
[4]. The standard treatment for high-grade glioma patients consists
of maximal surgical resection followed by radiotherapy and
chemotherapy with temozolomide [4,5].
Temozolomide contributes therapeutic beneﬁts for glioma
patients because it induces sustained pro-autophagic effects [6]
that then lead to apoptotic-related cell death [7] as a conse-
quence but not caused by the temozolomide-induced anti-glioma
effects [4]. These temozolomide-induced sustained pro-autophagic
effects circumvent, at least partly, the intrinsic resistance of glioma
cells to direct pro-apoptotic insults [2,4]. Temozolomide also
contributes therapeutic beneﬁts in glioma patients because of its
E. Gofﬁn et al. / European Journal of Medicinal Chemistry 54 (2012) 834e844 835anti-angiogenic effects [8]. However, the 5-year survival of GBM
patients remains as low as 10% [5] and new types of treatment are
mandatory to improve GBM-patient-related survivals. One possi-
bility would be to target some ion channels that are overexpressed
and/or overactivated in glioma cells as compared to normal glial
cells or neurons. Indeed, glioma cells release neurotransmitters,
their transporters, and ion channels to support their unusual
growth and invasive migration [9e12]. We have already demon-
strated that a signiﬁcant proportion of glioblastoma overexpress
the alpha-1 subunit of Naþ/Kþ-ATPase, whose inhibition leads to
pronounced autophagy-related cell death in glioma cells [13].
Ongoing clinical trials demonstrate that an inhibitor of chloride
channels may be a therapy for the treatment of gliomas [14].
Inourefforts todevelopnewchromanderivativesas cromakalim-
related potassium-channel openers, we previously synthesized
a large number of compounds, some of which showed very inter-
esting pharmacological proﬁles as activators of the ATP-sensitive
potassium channels (KATP channels) [15e20]. Such potassium-
channel openers are known to interact with the sulfonylurea
receptor (SUR) subunit of the KATP channel. The latter channel is an
octameric complex resulting from the combination of four SUR
subunitswith fourKir (potassium inwardly rectifying) subunits, both
of which exist in several isoforms (SUR1, SUR2A, and SUR2B; Kir6.1
and Kir6.2) [21]. Kir channels are also implicated in glioma cell
biology [22,23]. Recently, it was reported that the SUR1 subunit
associated to the transient receptorpotential “melastatin”4 (TRPM4)
channel protein (forming the NCCaeATP channel) was overexpressed
in glial cells under ischemic conditions [24]. It is tempting to spec-
ulate that the SUR1/TRPM4 channel could also be implicated in the
metabolismof glial tumor cells. Therefore, itwas decided to examine
the in vitro effects of these chroman-type potassium-channel
openers and related structures on the growth of three human high-
grade glioma cell lines, i.e. U373 and T98G from astroglial origin
[25e27] and Hs683 from oligodendroglial origin [25,26,28]. While
the Hs683model displays actual sensitivity to pro-apoptotic stimuli
[25,29], the U373 [25,29] and T98G [29] models do not.
The effects of various compounds were monitored by means of
quantitative videomicroscopy [30] using the U373 GBM astroglial
model in order to grossly decipher the mechanisms of action of
these compounds, i.e. to determine whether they display cytotoxic
versus cytostatic effects. Moreover, their effect on cell cycle was
investigated by ﬂow cytometry. Lastly, the bioselectivity (thus
toxicity) between normal astrocytes and glioma cells in terms of
in vitro growth inhibition was also investigated for several
compounds of interest.
2. Chemistry
The synthesis of compounds 1e4 (Fig. 1) has been described











Fig. 1. Previously described chromanwere prepared by condensation between 3-chlorobenzylamine
5 and the appropriate isothiocyanate (Scheme 1). For the N-
(5-chloro-2-methoxyphenyl)methylthioureas 9aeb, 5-chloro-
2-methoxybenzonitrile 7 was ﬁrst reduced to produce the corres-
ponding benzylamine derivative 8, whichwas then condensedwith
the appropriate isothiocyanate (Scheme 2).
6-Chlorochromans 16aeb were obtained from p-chlorophenol
in six steps (Scheme 3). p-Chlorophenol 10was ﬁrst alkylated using
3-bromopropionic acid under alkaline conditions. The reaction
never came to completion but the expected compound was easily
separated from the starting material using extraction from an ethyl
acetate solution by a solution of sodium hydrogen carbonate, re-
acidiﬁcation of the aqueous alkaline solution, and collection by
ﬁltration of the resulting precipitate consisting of compound 11. A
ring closure reaction of 4-chlorophenoxypropanoic acid 11 by
means of concentrated sulfuric acid produced the expected core
structure 12 as described previously [31].
After reduction of the ketone to alcohol 13 using sodium boro-
hydride [32], a Ritter reaction produced the corresponding
4-acetylamino derivative 14 using acetonitrile and concentrated
sulfuric acid. The subsequenthydrolysis of14with ahydro-ethanolic
solution of hydrochloric acid led to the 4-aminochroman 15. The
latter was ﬁnally converted into the expected thioureas after reac-
tion with the appropriate isothiocyanates.
All the compounds were crystallized from appropriate solvents
and characterized by 1H NMR. Their purity was assessed by
elemental analysis to obtain the ﬁnal materials with the chemical
purity required prior to pharmacological evaluations.
3. Results and discussion
3.1. Growth inhibitory activity (MTT colorimetric assay) on glioma
cells
The ﬁrst group of 6-chlorochroman compounds (Table 1) tested
on glioma cells were characterized by the presence of a variety of
functional groups at the 4-position and mainly included ureas (1b,
1c, 1f, and 1h) and thioureas (1d, 1e, and 1i), but also an acetamide
(1a), a sulfonylurea (1g), and a carbamate (1j) compound. None of
them showed marked in vitro growth inhibitory activity on the
three glioma cell lines (IC50 > 50 mM) but compounds 1f,1h, and 1i
revealed that the presence of a phenyl ring increased the growth
inhibition (see for example IC50 on T98G between 15 and 37 mM).
The second group of tested compounds (Table 2) included
benzylureas and benzylthioureas structurally related to 1f and
examined the inﬂuence of the nature of the halogen atom at the
6-position. It was found that 6-F (2a, 2c) and 6-Br (2b, 2e)
compounds showed a higher glioma growth inhibitory effect than
6-Cl (1f, 2d), while no signiﬁcant differences were observed
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Scheme 1. Synthesis of N-(3-chlorophenyl)methylthioureas. Reagant: 4- or 3-
nitrophenyl isothiocyanate, CH2Cl2.
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phenylthioureas structurally related to 1h and 1i (Table 3). The
monosubstitution of the phenyl ring by a chlorine atom at the three
possible positions (ortho,meta, and para) as well as the presence of
various halogen atoms at the 6-position were examined ﬁrst. Most
of the phenylureas (3aei) except 3h were found to be more active
(in terms of glioma growth inhibition in vitro) than 1h in the three
glioma cell lines under study, but none of them showed an
IC50 < 10 mM (Table 3).
The phenylthioureas 4aec structurally related to 1iwere equally
or more potent than their corresponding phenylureas 3gei, some
of them expressing IC50 values <10 mM on speciﬁc cancer cell lines
(4a on T98G, 4b on the three cell lines, 4c on U373 and Hs683; see
Table 3).
As a result, we focused on phenylthioureas bearing either an
electron-donating group (4def) or an electron-withdrawing group
(4ger) (Table 3). While the introduction of an electron-donating
group (methoxy) on the phenyl ring (4def) did not induce any
marked improvement of the in vitro growth inhibitory activity
compared to the unsubstituted derivative 1i, the introduction of an
electron-withdrawing group (cyano or nitro) (4ger) markedly
increased this growth inhibitory activity (Table 3). Most of the
compounds showed IC50  10 mM on glioma cells and the best
results (IC50 < 5 mM) were obtained with nitro-substituted
compounds in the 6-Cl series (4o and 4p), showing IC50 values
between 2 and 4 mM on the three cell lines and reaching the effects
displayed by cisplatin (Table 3). Temozolomide and cisplatin were
used as reference compounds because temozolomide is currently
the preferred drug used for the treatment of glioblastoma [4e7]
and platinum derivatives are used to treat recurrent gliomas that
relapse during temozolomide treatment [33]. Temozolomide
revealed a modest in vitro antiproliferative activity on glioma cells
(Table 3).
As 4o and 4p were the most potent compounds, it was decided
to investigate the importance of the integrity of the 2,2-







Scheme 2. Synthesis of N-(5-chloro-2-methoxyphenyl)methylthioureas. ReSimpliﬁed derivatives were synthesized and the biological results
are shown in Table 4. After each step of simpliﬁcation [C-2 deme-
thylation (see 16aeb), ring opening by C-3 removal (see 9aeb),
demethoxylation (see 6aeb)], a gradual decrease of the activity
was observed, with IC50 around 6e10 mM for the non-methylated
compounds 16a and 16b, around 15e35 mM for compounds 9a
and 9b, and around 30e60 mM for the fully open cores 6a and 6b
(Table 4).
These results highlight the critical importance of the integrity of
the 2,2-dimethylchroman core structure for activity on cancer cells.
Even if this nucleus is well known in the literature, little has
appeared on examples of such compounds expressing in vitro
antitumor activity. Recently, however, a series of chromans bearing
a piperidine ring linked through a spiro carbon atom at the 2-
position, such as the 4-acylamino-substituted compound 17
(Fig. 2), were described as histone deacetylase inhibitors and were
found to exert marked antiproliferative activity [34]. Concerning
more speciﬁcally N-aryl-N0-(chroman-4-yl)ureas or thioureas, two
recent works described compounds like 18 and 19 (Fig. 2) as potent
TRPV1 receptor antagonists [35,36]. For themoment, it is not known
if such compounds also exert antiproliferative activity on glioma
cells and/or if the antagonism of TRPV1 receptors could explain the
antiproliferative activity of our tightly related chromans.
Considering that the active drugs have to cross the blood brain
barrier (BBB) and to reach the central nervous system (CNS), it was
important to consider their lipophilic character, which can be
appreciated by examining their log P values. Although it is difﬁcult
to predict the optimal log P value required for a drug to cross the
BBB and to penetrate into the CNS, literature reports that the mean
clog P (calculated log P) value established for CNS drugs is higher
than that of non-CNS drugs (3.43 versus 2.78) [37] and, in accor-
dance with the Lipinski rule of ﬁve, may not exceed a value of 5
[38,39].
Table 3 reports the AClog P values (calculated log P values
according to the ALOGPS 2.1 software [40]) of the most potent
chromans and of the reference drug temozolomide. The latter drug
is known to reach the CNS and to act on tumor glial cells.
Surprisingly, the AClog P value of 1.14 obtained with temozolo-
mide is representative of a hydrophilic rather than a lipophilic drug.
On the contrary, most of the chromans were expected to be highly
lipophilic drugs with AClog P values calculated between 4.0 and 5.4.
At least, it is concluded that the chroman-type non-ionic small
molecules express appropriate theoretical druglikeness to become
centrally active compounds.
Interestingly, recent literature reported that chroman-type KATP
channel openers such as bimakalim (AClog P ¼ 2.71) need to cross
the phospholipid bilayer of cell membranes to penetrate into the
cell and then to interact with their receptors on the SUR subunit via
the cytosol [41]. Since most of the active chromans on glioma cells
are also known to be active as KATP channel openers, it is tempting
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agents: (a) LiAlH4, THF; (b) 4- or 3-nitrophenyl isothiocyanate, CH2Cl2.
Table 2






Compounds Y X In vitro IC50 growth inhibitory concentrations
(mM)a
U373 T98G Hs683 Mean  SEM
2ab O F 11  2 49  3 19  1 26  12
1fb O Cl 66  11 15  3 47  4 43  15
2bb O Br 27  1 38  12 38  3 34  4
2cb S F 27  1 40  1 25  1 31  5
2db S Cl 64  14 99  11 43  3 69  16
2eb S Br 29  2 54  5 34  3 39  8
a IC50 values (mM): concentration of drug (mM) responsible for the inhibition of
50% of the growth of the speciﬁed cell line after t ¼ 72 h [Mean  s.e.m. (n ¼ 6)].
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Scheme 3. Synthesis of 6-chlorochromans. Reagents: (a) BrCH2CH2COOH, KOH; (b) H2SO4; (c) NaBH4, CH3OH; (d) CH3CN, H2SO4; (e) HCl 25% in ethanolewater; (f) 4- or 3-
nitrophenyl isothiocyanate, CH2Cl2.
Table 1






Compounds Y R In vitro IC50 growth inhibitory
concentrations (mM)a
U373 T98G Hs683 Mean  SEM
1ab O CH3 >100 ee e e
1bb O NHCH2CH3 >100 e e e
1cb O NHCH(CH3)2 62  2 >100 85  2 > 82
1db S NHCH2CH3 96  4 >100 72  3 > 89
1eb S NHCH(CH3)2 57  1 91  3 34  2 61  16
1fb O NHCH2C6H5 66  11 15  3 47  4 43  15
1gb O NHSO2C6H5 96  4 >100 >100 > 99
1hc O NHC6H5 68  8 34  2 33  3 45  12
1id S NHC6H5 46  1 37  1 32  2 38  4
1jb O OCH2CH3 >100 e e e
a IC50 values (mM): concentration of drug (mM) responsible for the inhibition of
50% of the growth of the speciﬁed cell line after t ¼ 72 h [Mean  s.e.m. (n ¼ 6)].
b Published compounds in Ref. [15].
c Published compounds in Ref. [16].
d Published compounds in Ref. [17].
e “e” ¼ not determined.
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Compounds X Y R In vitro IC50 growth inhibitory concentrations (mM)a Mean  SEM B16F10 melanoma mouse Sel.e AClog Pf
U373 glioma human T98G glioma human Hs683 glioma human
1hb Cl O H 68  8 34  2 33  3 45  6 e eg 4.44
1ic Cl S H 46  1 37  1 32  2 38  4 e e 4.74
3ab F O 2-Cl 40  1 27  1 29  1 32  4 e e 4.50
3bb F O 3-Cl 39  2 45  1 38  2 41  2 e e 4.50
3cb F O 4-Cl 24  1 30  1 25  1 26  2 e e 4.50
3db Cl O 2-Cl 17  2 20  3 25  2 20  3 20  3 >10 5.05
3eb Cl O 3-Cl 21  1 25  1 17  2 21  2 25  1 >10 5.05
3fb Cl O 4-Cl 19  2 33  1 22  1 25  4 32  2 w5 5.05
3gb Br O 2-Cl 19  2 11  3 22  2 17  3 22  3 >10 5.14
3hb Br O 3-Cl 69  3 67  3 61  4 66  2 e e 5.14
3ib Br O 4-Cl 25  3 27  1 24  2 25  1 9  1 w5 5.14
4ac Br S 2-Cl 34  2 8  1 22  2 21  8 17  2 <5 5.43
4bc Br S 3-Cl 8  1 9  1 8  1 8  1 7  1 <2 5.43
4cc Br S 4-Cl 7  1 22  1 9  3 13  5 7  1 w2 5.43
4dc Br S 2-OCH3 22  1 42  3 40  1 35  6 e e 4.72
4ec Br S 3-OCH3 66  3 87  1 81  1 78  6 e e 4.72
4fc Br S 4-OCH3 40  2 33  1 29  1 34  3 e e 4.72
4gd F S 3-CN 30  3 39  2 33  1 34  3 35  3 e 3.99
4hd F S 4-CN 11  1 19  1 14  2 15  3 5  1 w3 3.99
4id Cl S 3-CN 7  1 10  1 6  2 8  1 6  1 <5 4.55
4jd Cl S 4-CN 10  1 10  1 6  1 9  1 7  1 w3 4.55
4kd Br S 3-CN 6  1 9  1 4  1 6  1 7  1 <5 4.63
4ld Br S 4-CN 22  2 24  1 15  3 20  3 e w2 4.63
4md F S 3-NO2 6  1 9  1 6  1 7  1 6  1 w2 4.19
4nd F S 4-NO2 3  1 5  1 3  1 3  1 4  1 w5 4.19
4od Cl S 3-NO2 3  1 4  1 3  1 3  1 6  1 w3 4.74
4pd Cl S 4-NO2 3  1 4  1 2  1 3  1 3  1 w2 4.74
4qd Br S 3-NO2 4  1 4  1 3  1 4  1 5  1 w2 4.83
4rd Br S 4-NO2 9  4 5  1 3  1 6  1 3  1 <2 4.83
Temozolomide 220  48 879  34 956  35 685  23 258  52 e 1.14
Cisplatin 4  1 12  4 4  1 7  3 24  4 e e
a IC50 values (mM): concentration of drug (mM) responsible for the inhibition of 50% of the growth of the speciﬁed cell line after t ¼ 72 h [Mean  s.e.m. (n ¼ 6)].
b Published compounds in Ref. [16].
c Published compounds in Ref. [17].
d Published compounds in Ref. [18].
e “Sel” means the level of selectivity, i.e. IC50 concentrations obtained on normal astrocytes (n ¼ 3)/IC50 concentrations obtained on tumor astrocytes (n ¼ 3).
f AClog P: calculated log P values according to the ALOGPS 2.1 software [40].
g “e” ¼ not determined.
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the BBB.
3.2. Comparison between activity on KATP-channel-expressing cells
and glioma cells
Taken together, the data reported in Tables 1e3 tentatively indi-
cated a relationship between the efﬁcacy of 2,2-dimethylchromans
on pancreatic b-cells (KATP-channel-expressing tissue) and on
glioma cells (with unknown KATP-channel-expressing patterns of
expression). Indeed, previous works have revealed that among
several seriesofchromansdistinguishedbythenatureof thechemical
moiety at the 4-position (acetamides, arylsulfonylureas, carbamates,
aralkylureas/thioureas, arylureas/thioureas), arylureas and arylthio-
ureaswere found tobe themostpotent inhibitors of insulin release, as
a result of their opening activity on the SUR1-type KATP channels
[15e18]. Interestingly, the same observation was made with respect
to glioma cell growth rates in that arylurea-/arylthiourea-typechromans were also found to be the most efﬁcient in vitro growth
inhibitory agents, supporting the view that a putative SUR1-type K
channel, affected by suchmolecules, could be expressed by astroglial
tumor cells and involved in their cell survival and proliferation
(Table 3). After careful examination, however, some discrepancies
were noticedwith respect to the nature and the position (ortho,meta,
or para) of the substituent on the phenyl ring of arylureas and
arylthioureas. Indeed, methoxy-substituted compounds were found
to be less active on b-cells as well as on glioma cells than chloro-,
cyano-, and nitro-substituted compounds [17,18]. However, chloro-,
cyano-, and nitro-substituted compounds were almost equally
effective on b-cells [17,18], while the rank order of potency on glioma
cells appeared to be nitro- > cyano- > chloro-compounds (Table 3).
Moreover, looking at the chloro-compounds in the arylurea-type
chroman series, although the ortho position was less favorable for
activity on pancreatic b-cells [16,17], no clear differences were found
between ortho-, meta-, and para-substituted chloro-compounds for
growth inhibitory activity on glioma cells (Table 3).
Table 4



















6a-b                        9a-b                           16a-b 
Compounds R In vitro IC50 growth inhibitory
concentrations (mM)a
U373 T98G Hs683
6a 4-NO2 27  1 20  5 27  2
6b 3-NO2 32  1 61  2 41  2
9a 4-NO2 22  1 35  2 15  2
9b 3-NO2 32  2 e 23  2
16a 4-NO2 8  1 12  1 6  1
16b 3-NO2 8  1 10  1 7  1
a IC50 values (mM): concentration of drug (mM) responsible for the inhibition of
50% of the growth of the speciﬁed cell line after t ¼ 72 h [Mean  s.e.m. (n ¼ 6)];
“e” ¼ not determined.
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opening potency of drugs and their growth inhibitory activity, we
tested several reference compounds known to be KATP-channel
openers or blockers. Thus, 6-chloro-7-ﬂuoro-3-isopropylamino-
4H-1,2,4-benzothiadiazine 1,1-dioxide (a strong SUR1-type KATP-
channel opener [19]), 7-chloro-3-(1,1-dimethylpropyl)amino-4H-
1,2,4-benzothiadiazine 1,1-dioxide (expected to be a SUR2B-type
KATP-channel opener [20]), R/S-pinacidil (a SUR2B-type KATP-
channel opener), and glibenclamide (a KATP-channel blocker) were
assayed in terms of glioma growth inhibitory activity by means of
theMTTcolorimetric assay in human U373 glioblastoma cells. None
of these reference compounds (three openers and one blocker)
expressed a marked growth inhibitory activity (IC50 > 100 mM)













Fig. 2. 4-Acylamino/ureido-substituted chromans reported as histone deprobably not involved in the in vitro anti-glioma growth inhibitory
activity of arylurea- and arylthiourea-type chromans.
3.3. Selectivity for tumor glial cells versus normal glial cells
For compounds whose mean IC50 value was found to be <30 mM
on the threehumanglioma cell lines,weanalyzed their selectivity by
quantiﬁcation of their activity on the in vitro growth inhibition in
normal mouse astrocytes (Table 3). The results of this analysis
showed a clear distinction of cell selectivity between phenylureas
and phenylthioureas (Table 3). All phenylurea derivatives presented
a selectivity ratio5when dividing themean IC50 growth inhibitory
concentrations calculated on normal astrocytes by those IC50
concentrations calculated on the human glioma cell lines (Table 3).
This selectivity index increased to>10 for 3d, 3e, and3g (Table 3). On
the contrary, all thioureas showedaselectivity ratiobelow5(Table3).
As the in vitro growth inhibitory activity of the compounds
under study were analyzed on human glioma cell lines, while the
bioselectivity was determined onmouse normal astrocytes, we also
analyzed the in vitro growth inhibitory activity of the bioselective
compounds detailed in Table 3 on a mouse melanoma pseudome-
tastasis brain model [42] in order to rule out differences that could
relate to interspecies features. The data in Table 3 clearly indicate
that mouse and human cancer cells display similar sensitivity to the
compounds under study.
3.4. Cell cycle analysis
We noticed no differences in terms of growth inhibitory
activity (as revealed by the MTT colorimetric assay; Tables 1e4)
for all compounds under study when comparing glioma cells
actually sensitive to pro-apoptotic stimuli (the Hs683 glioma cells
[25,29]) to glioma cells displaying various levels of resistance to
pro-apoptotic stimuli (the U373 [25,29] and T98G [29] glioma
cells). These data thus suggest that the compounds under study
exert their effects through non-apoptotic pathways. Cell cycle
kinetics of U373 glioma cells were thus performed to provide
insights about the mechanism of action between the most active







acetylase inhibitors (17) or TRPV1 receptor antagonists (18 and 19).
Fig. 3. Cell cycle analysis by ﬂow cytometry. Human U373 glioblastoma cells were treated with the indicated chroman derivatives at the indicated concentrations (corresponding
approximately to half and double of the IC50 growth inhibitory concentration revealed by the MTT colorimetric assay) for 24 h. Percentage of cells in G0/G1 phase is signiﬁcantly
higher than cells treated with vehicle only with p value < 0.01 (**) or with p value< 0.001 (***); n ¼ 3.
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4c, 4n, 4o, and 4p (with IC50  7 mM) (Table 3). The data in Fig. 3
conﬁrm the non-apoptotic-mediated growth inhibitory effects of
the most active compounds under study according to the fact that
none of the compounds markedly increased the percentage of
subG1 U373 glioma cells.
The cell cycle kinetic analyses did not allow a clear distinction to
be made between all these compounds because all of them blocked
more or less the cell cycle in the G0/G1 phase (Fig. 3). In contrast,
cell cycle analysis provided important information. Indeed, because
the compounds under study are known to modify KATP-channel
activity (as detailed in the Introduction), we also analyzed the effect
of the KATP-channel opener pinacidil (30 and 100 mM) and the KATP-
channel blocker glibenclamide (10 and 30 mM) on U373 cell cycleFig. 4. Quantitative videomicroscopy-related illustrations of the cytostatic effects induced
induces cytotoxic effects (Gx200).kinetics. The data in Fig. 3 show that these two compounds did not
modify U373 cell cycle kinetics. These data therefore suggest that
the compounds under study exert their growth inhibitory effects on
glioma cell growth independently of KATP-channel activity through
an as yet unknown mechanism.
3.5. Quantitative videomicroscopy-related analyses
In addition to the cell cycle kinetic analyses, computer-assisted
phase-contrast microscopy (quantitative videomicroscopy) was
used to provide further information about mechanisms of action.
Thus, 3d, 3e, and 3g, i.e. the three compounds under study among
the most active ones associated with the highest bioselectivity
(Table 3), were analyzed to discover if they displayed cytotoxic orby 3d (20 mM) and 3g (20 mM) in human U373 glioblastoma cells, while 3e (20 mM)
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glioma cell lines at 20 mM, i.e. a concentration close to their IC50
growth inhibitory concentration as revealed by the MTT colori-
metric assay (Table 3). This 20 mM concentration turned out to
correspond to an IC80 (quantitative videomicroscopy) rather than to
an IC50 (MTT colorimetric assay) growth inhibitory concentration
with respect to each compound analyzed (data not shown). The
IC80 concentration was determined as follows: in both control and
treated conditions, U373 glioma cell growth levels were evaluated
by the ratio between the numbers of cells counted in the last and
ﬁrst frames of the image sequences. A global growth ratio (GGR)
was thus determined as the ratio between the two growth levels
obtained in the treated and control conditions. GGR values were
equal to 0.2 (thus to an IC80 growth inhibitory concentration) for
each of the three compounds analyzed at 20 mM. The fact that
20 mM appeared more active for each of the three compounds
analyzed under quantitative videomicroscopy than under MTT
colorimetric assay could relate, at least partly, to distinct cell culture
conditions. Indeed, in the MTT test, cells are cultured in 100 mL cell
culture volumes in 96-well microplates, while they are cultured in
25 cm2 ﬂasks containing 7mL culturemedium in the other test. The
morphological illustrations in Fig. 4 and the dynamic movies (data
not shown) clearly indicate that 3d and 3g are cytostatic at their
IC80 growth inhibitory concentrations, while 3e is cytotoxic at its
IC80 concentration. It thus seems that the position of the chlorine
atom on the phenyl ring (o-, m- or p-position) is of critical impor-
tance since only the ortho-substituted chloro-compounds 3d and
3g, but not the meta-substituted chloro-compound 3e, were found
to be clearly cytostatic.
4. Conclusions
Based on the ongoing clinical study using a chloride-channel
blocker as a treatment for glioma, we examined a series of 2,2-
dimethylchromans previously reported as potassium-channel
openers, as well as some newly synthesized simpliﬁed structures,
for their in vitro growth inhibitory activity on three human high-
grade glioma cell lines, U373, T98G, and Hs683. A marked growth
inhibitory activity was observed with 2,2-dimethylchroman-type
phenylureas and phenylthioureas, among which nitro-substituted
phenylthioureas, such as compounds 4o and 4p, were recognized
as the most efﬁcient (but also poorly selective) derivatives on
glioma cells. Selected phenylureas (3d, 3e, 3g) were found to be less
active, butmore cell selective (normal versus tumor glial cells), thus
less toxic, than the corresponding phenylthioureas. Furthermore,
these most active and bioselective phenylureas (3d, 3e, 3g) dis-
played similar growth inhibitory concentrations between glioma
cells that display actual sensitivity to pro-apoptotic stimuli (the
Hs683 glioma model) and glioma cells that display various levels of
resistance to pro-apoptotic stimuli (the U373 and T98G glioma
models). In future studies of new active substances belonging to
this class of compounds, it will be important to ﬁnd the best
equilibrium between activity and selectivity.
Arylurea-/arylthiourea-type chromans, known to interact with
SUR1-type KATP channels, were found to be the most efﬁcient
in vitro growth inhibitory agents, supporting the view that a puta-
tive SUR1-type K channel, affected by such molecules, could be
expressed on astroglial tumor cells and involved in their antitumor
activity. However, none of the reference KATP-channel openers and
blockers, tested on the U373 cell line to conﬁrm such an assump-
tion, revealed a signiﬁcant growth inhibitory activity, demon-
strating that no clear relationship could be found between the
potency of chromans as potassium channel openers and their
growth inhibitory activity on glioma cells. Computer-assisted
phase-contrast videomicroscopy indicated that minor chemicalmodiﬁcations were sufﬁcient to transform cytostatic compounds
into cytotoxic ones and ﬂow cytometry showed that these
compounds exert their growth inhibitory effects by blocking the
cell cycle in the G0/G1 phase. As a result, this work identiﬁed
phenylurea- and phenylthiourea-type 2,2-dimethylchromans as
new classes of antitumor agents to be further explored for an
innovative therapeutic approach of high-grade glioma in humans.
5. Experimental section
5.1. Chemistry
Melting points were determined on a Stuart SMP3 capillary
apparatus and are uncorrected. The 1H NMR spectra were recorded
on a Bruker Avance (500 MHz) instrument using d6-DMSO as the
solvent with TMS as an internal standard; chemical shifts are
reported in d values (ppm) relative to that of internal TMS. The
abbreviations s ¼ singlet, d ¼ doublet, t ¼ triplet, q ¼ quadruplet,
m ¼ multiplet, and b ¼ broad are used throughout. Elemental
analyses (C, H, N, S) were realized on a Thermo Scientiﬁc FlashEA
1112-elemental analyzer and were within 0.4% of the theoretical
values. This analytical method certiﬁed a purity 95% for each
tested compound. All reactions were routinely checked by TLC on
silica gel Merck 60 F254.
5.1.1. N-[(3-Chlorophenyl)methyl]-N0-(4-nitrophenyl)thiourea (6a)
4-Nitrophenyl isothiocyanate (0.15 g, 0.85 mmol) was added to
a solution of 3-chlorobenzylamine (0.1 g, 0.71 mmol) in methylene
chloride (2 mL). After 20 min at room temperature, the resulting
precipitate was collected by ﬁltration, washed with hexane and
dried (0.16 g, 70%): mp 130e132 C; 1H NMR (DMSO-d6) d 4.77 (s,
2H, CH2), 7.31e7.41 (m, 4H, C6H4Cl), 7.85 (d, J¼ 9 Hz, 2H, 20-H/60-H),
8.19 (d, J ¼ 9 Hz, 2H, 30-H/50-H), 8.72 (bs, 1H, CH2NH), 10.28 (bs, 1H,
NO2C6H4NH); 13C NMR (DMSO-d6) d 46.7 (CH2NH), 120.8 (C-20/C-
60), 124.5 (C-30/C-50), 126.2, 126.9, 127.2 (C-2/C-4/C-6), 130.2 (C-3),
132.9 (C-5), 141.0 (C-1), 142.0 (C-40), 146.2 (C-10), 180.6 (NHCSNH).
Anal. (C14H12ClN3O2S) theoretical: C, 52.26; H, 3.76; N, 13.06; S,
9.96. Found: C, 52.30; H, 3.80; N, 13.09; S: 9.60.
5.1.2. N-[(3-Chlorophenyl)methyl]-N0-(3-nitrophenyl)thiourea (6b)
The title compound was obtained as described for 6a, starting
from 3-chlorobenzylamine (0.1 g, 0.71 mmol) and 3-nitrophenyl
isothiocyanate (0.15 g, 0.85 mmol) (0.19 g, 83%): mp
149.5e151.5 C; 1H NMR (DMSO-d6) d 4.78 (s, 2H, CH2), 7.31e7.41
(m, 4H, C6H4Cl), 7.6 (t, J ¼ 8.2 Hz, 1H, 50-H), 7.85 (d, J ¼ 8.2 Hz,
1H, 60-H), 7.93 (d, J ¼ 8.2 Hz, 1H, 40-H), 8.59 (bs, 2H, 20-H/CH2NH),
10.09 (bs, 1H, NO2C6H4NH); 13C NMR (DMSO-d6) d 46.4 (CH2NH),
116.7 (C-20), 118.2 (C-40), 126.1, 126.9, 127.1 (C-2/C-4/C-6), 128.7 (C-
60), 129.7 (C-50), 130.2 (C-3), 132.9 (C-5), 140.9 (C-1), 141.3 (C-10),
147.5 (C-30), 181.1 (NHCSNH). Anal. (C14H12ClN3O2S) theoretical: C,
52.26; H, 3.76; N, 13.06; S, 9.96. Found: C, 52.08; H, 3.78; N, 13.05;
S: 9.69.
5.1.3. 5-Chloro-2-methoxybenzylamine (8)
Lithium aluminum hydride (0.34 g, 9 mmol) was added to
a solution of 5-chloro-2-methoxybenzonitrile (0.5 g, 3 mmol) in
tetrahydrofuran (10mL) at 0 C. Themixturewasmaintained at this
temperature for a further 30 min and then stirred for an additional
1 h at 30 C. After cooling at 0 C, water (50 mL) was added and the
amine was extracted twice with methylene chloride. The organic
layers were dried over magnesium sulfate, ﬁltered, and evaporated
under reduced pressure. The crude residue of the title compound
(0.35 g, 68%) was used directly in the next step (synthesis of 9a and
9b). 1H NMR (DMSO-d6) d 1.85 (bs, 2H, NH2), 3.64 (s, 2H, CH2), 3.77
(s,1H, OCH3), 6.94 (d, J¼ 8.7 Hz,1H, 3-H), 7.21 (dd, J¼ 8.7 Hz/2.7 Hz,
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The title compound was obtained as described for 6a, starting
from 8 (0.075 g, 0.44 mmol) and 4-nitrophenyl isothiocyanate
(0.095 g, 0.53 mmol) (0.06 g, 40%): mp 188e190 C; 1H NMR
(DMSO-d6) d 3.85 (s, 3H, OCH3), 4.69 (s, 2H, CH2), 7.05 (d, J ¼ 8.8 Hz,
1H, 3-H), 7.25 (d, J ¼ 2.2 Hz, 1H, 6-H), 7.32 (dd, J¼ 9.1 Hz/2.7 Hz, 1H,
4-H), 7.88 (d, J ¼ 9 Hz, 2 H, 20-H/60-H), 8.19 (d, J ¼ 9 Hz, 2H, 30-H/50-
H), 8.55 (bs, 1H, CH2NH), 10.3 (bs, 1H, NO2C6H4NH); 13C NMR
(DMSO-d6) d 42.2 (CH2NH), 55.8 (OCH3), 112.4 (C-3), 120.5 (C-20/C-
60), 123.9 (C-5), 124.5 (C-30/C-50), 127.7, 127.8 (C-4/C-6), 127.9 (C-1),
141.9 (C-40), 146.3 (C-10), 155.6 (C-2), 180.5 (NHCSNH). Anal.
(C15H14ClN3O3S) theoretical: C, 51.21; H, 4.01; N, 11.94; S, 9.14.
Found: C, 51.24; H, 4.04; N, 12.01; S: 8.74.
5.1.5. N-[(5-Chloro-2-methoxyphenyl)methyl]-N0-(3-nitrophenyl)
thiourea (9b)
The title compound was obtained as described for 6a, starting
from 8 (0.2 g, 1.17 mmol) and 3-nitrophenyl isothiocyanate (0.25 g,
1.4 mmol) (0.3 g, 73%): mp 169e172 C; 1H NMR (DMSO-d6) d 3.84
(s, 3H, OCH3), 4.7 (s, 2H, CH2), 7.04 (d, J ¼ 8.8 Hz, 1H, 3-H), 7.24 (d,
J ¼ 2.2 Hz, 1H, 6-H), 7.32 (dd, J ¼ 8.7 Hz/2.6 Hz, 1H, 4-H), 7.59 (t,
J ¼ 8.2 Hz, 1H, 50-H), 7.87 (d, J ¼ 7.6 Hz, 1H, 60-H), 7.93 (d, J ¼ 8.1 Hz,
1H, 40-H), 8.37 (bs, 1H, CH2NH), 8.65 (s, 1H, 20-H), 10.11 (bs, 1H,
NO2C6H4NH); 13C NMR (DMSO-d6) d 42.1 (CH2NH), 55.8 (OCH3),
112.4 (C-3), 116.4 (C-20), 118.1 (C-40), 123.9 (C-5), 127.5, 127.7 (C-4/C-
6), 128.2 (C-1), 128.4 (C-60), 129.7 (C-50), 141.0 (C-10), 147.5 (C-30),
155.5 (C-2) 181.0 (NHCSNH). Anal. (C15H14ClN3O3S) theoretical: C,
51.21; H, 4.01; N, 11.94; S, 9.14. Found: C, 50.89; H, 3.98; N, 11.95;
S: 8.44.
5.1.6. 3-(4-Chlorophenoxy)propanoic acid (11)
A mixture of 4-chlorophenol (10 g, 78.1 mmol), 3-
bromopropionic acid (11.9 g, 78.1 mmol), potassium hydroxide
(8 g, 0.2 mol) and ethanol (5 mL) in water (80 mL) were reﬂuxed
overnight. After cooling, the solution was acidiﬁed with concen-
trated hydrochloric acid to pH¼ 1 and extracted with ethyl acetate.
The organic layer was washed with a saturated aqueous solution of
sodium bicarbonate. The aqueous phase was then acidiﬁed with
concentrated hydrochloric acid and extracted with ethyl acetate.
The ﬁnal organic layer was dried over magnesium sulfate, ﬁltered,
and evaporated under vacuum. The title product was recrystallized
in ethyl acetate/hexane (1:5). The resulting precipitate was
collected by ﬁltration, washed with hexane, and dried (3.6 g, 23%):
mp 136e138 C; 1H NMR (DMSO-d6) d 2.68 (t, J ¼ 6 Hz, 2H,
CH2COOH), 4.15 (t, J ¼ 6 Hz, 2H, OCH2), 6.96 (d, J ¼ 9 Hz, 2H, 2-H/6-
H), 7.32 (d, J ¼ 9 Hz, 2H, 3-H/5-H), 12.38 (bs, H, COOH); 13C NMR
(DMSO-d6) d 34.0 (CH2COOH), 63.9 (OCH2), 116.2 (C-2/C-6), 124.3
(C-4), 129.2 (C-3/C-5), 157.2 (C-1), 172.1 (COOH).
5.1.7. 6-Chlorochroman-4-one (12)
A mixture of 11 (2 g, 10 mmol) and concentrated sulfuric acid
(20 mL) was stirred at room temperature for 1 h, poured onto ice
and extracted with ethyl acetate. The organic layer was washed
twice with saturated aqueous sodium bicarbonate, dried over
magnesium sulfate, ﬁltered, and evaporated under vacuum. The
title product was recrystallized in ethyl acetate/hexane (1:5). The
resulting precipitate was collected by ﬁltration, washed with
hexane, and dried (1 g, 55%): mp 98e101 C (lit. [31]: mp
100e101 C); 1H NMR (DMSO-d6) d 2.82 (t, J ¼ 6.5 Hz, 2H, 3-H2),
4.56 (t, J ¼ 6.5 Hz, 2H, 2-H2), 7.1 (d, J ¼ 8.9 Hz, 1H, 8-H), 7.6 (dd,J ¼ 8.9 Hz/2.7 Hz, 1H, 7-H), 7.68 (d, J ¼ 2.7 Hz, 1H, 5-H); 13C NMR
(DMSO-d6) d 36.8 (C-3), 66.9 (C-2), 120.3 (C-8), 122.0 (C-4a/C-6),
125.3 (C-5), 135.6 (C-7), 160.1 (C-8a), 190.6 (C-4).
5.1.8. R/S-6-Chlorochroman-4-ol (13)
Sodium borohydride (0.46 g, 12.1 mmol) was added to a stirred
suspension of 12 (2 g, 11 mol) in methanol (30 mL) at 0 C, and the
mixture was maintained at this temperature for a further 30 min.
The mixture was stirred for an additional 30 min at room
temperature and the solvent was evaporated under vacuum. Water
was added to the residue, the suspensionwas acidiﬁed by means of
concentrated hydrochloric acid and the product was extracted
twice with methylene chloride. The organic layers were dried over
magnesium sulfate, ﬁltered, and evaporated under vacuum. The
title product was recrystallized in ethyl acetate/hexane (1:5). The
resulting precipitate was collected by ﬁltration, washed with
hexane, and dried (1.7 g, 84%): mp 80e83 C (lit. [32]: mp
91e93 C); 1H NMR (DMSO-d6) d 1.81e2 (m, 2H, 3-H2), 4.18
(t, J ¼ 5.1 Hz, 2H, 2-H2), 4.61 (qd, J ¼ 5.1 Hz, 1H, 4-H), 5.5 (d,
J ¼ 5.1 Hz, 1H, OH), 6.77 (d, J ¼ 8.7 Hz, 1H, 8-H), 7.16 (dd, J ¼ 8.7 Hz/
2.6 Hz, 1H, 7-H), 7.32 (d, J ¼ 2.6 Hz, 1H, 5-H); 13C NMR (DMSO-d6)
d 30.5 (C-3), 61.3 (C-4), 62.6 (C-2), 118.0 (C-8), 123.3 (C-6), 128.2
(C-4a), 128.3 (C-7), 128.9 (C-5), 152.9 (C-8a). Anal. (C9H9ClO2)
theoretical: C, 58.55; H, 4.91. Found: C, 57.83; H, 4.82.
5.1.9. R/S-4-Acetamido-6-chlorochroman (14)
A suspension of 13 (1.7 g, 9.24 mmol) in acetonitrile (33mL) was
added dropwise to a stirred solution of 98% sulfuric acid (1.1 mL) in
acetonitrile (7 mL) kept between 10 and 0 C. The mixture was
allowed to warm to room temperature during 1 h. The solutionwas
poured into cold water, and the precipitate was collected by
ﬁltration, washed with water, and dried (2 g, 96%): mp 190e192 C;
1H NMR (DMSO-d6) d 1.81e2.05 (m, 2H, 3-H2), 1.88 (s, 3H,
NHCOCH3), 4.2 (m, 2H, 2-H2), 4.98 (qd, J ¼ 7 Hz, 1H, 4-H), 6.81 (d,
J ¼ 8.7 Hz, 1H, 8-H), 7.15 (d, J ¼ 2.3 Hz, 1H, 5-H), 7.18 (dd, J ¼ 8.7 Hz/
2.6 Hz, 1H, 7-H), 8.36 (d, J ¼ 8 Hz, NHCOCH3); 13C NMR (DMSO-d6)
d 22.6 (CH3), 28.2 (C-3), 42.2 (C-4), 63.5 (C-2), 118.3 (C-8), 123.7
(C-6), 125.6 (C-4a), 128.3 (C-7), 128.4 (C-5), 153.5 (C-8a), 168.9
(COCH3). Anal. (C11H12ClNO2) theoretical: C, 58.55; H, 5.36; N, 6.21.
Found: C, 58.63; H, 5.38; N, 6.24.
5.1.10. R/S-4-Amino-6-chlorochroman (15)
A solution of 14 (1 g, 4.44 mmol) in concentrated hydrochloric
acid (14 mL) and ethanol (7 mL) was reﬂuxed for 72 h. Hydrochloric
acid and ethanol were removed under vacuum, and the residuewas
dissolved in hot water (20 mL). The solution was ﬁltered, 10%
aqueous sodium hydroxide was added to the ﬁltrate until alkaline
and the amine was extracted twice with methylene chloride. The
organic layers were dried over magnesium sulfate, ﬁltered, and
evaporated under reduced pressure. The pure residue (0.6 g, 74%)
was used directly in the next step (synthesis of 9a and 9b). 1H NMR
(DMSO-d6) d 1.68e2.01 (m, 2H, 3-H2), 1.99 (bs, 2H, NH2), 3.86
(t, J¼ 5.8 Hz,1H, 4-H), 4.1e4.26 (m, 2H, 2-H2), 6.73 (d, J¼ 8.7 Hz,1H,
8-H), 7.1 (dd, J¼ 8.7 Hz/2.6 Hz,1H, 7-H), 7.44 (d, J¼ 2.6 Hz,1H, 5-H);
13C NMR (DMSO-d6) d 25.9 (C-3), 43.2 (C-4), 62.0 (C-2), 118.9 (C-8),
120.7 (C-6), 123.8 (C-4a), 129.1 (C-5), 129.9 (C-7), 153.6 (C-8a).
5.1.11. R/S-N-[6-Chlorochroman-4-yl]-N0-(4-nitrophenyl)thiourea
(16a)
The title compound was obtained as described for 6a, starting
from 15 (0.15 g, 0.82 mmol) and 4-nitrophenyl isothiocyanate
(0.18 g, 1 mmol) (0.28 g, 94%): mp 204e206 C; 1H NMR (DMSO-d6)
d 2.06e2.26 (m, 2H, 3-H2), 4.25 (m, 2H, 2-H2), 5.63 (m, 1H, 4-H),
6.86 (d, J¼ 8.7 Hz,1H, 8-H), 7.24 (dd, J¼ 8.7 Hz/2.6 Hz,1H, 7-H), 7.33
(d, J ¼ 2.6 Hz, 1H, 5-H), 7.88 (d, J ¼ 9 Hz, 2 H, 20-H/60-H), 8.19
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1H, NO2C6H4NH); 13C NMR (DMSO-d6) d 27.4 (C-3), 47.3 (C-4), 63.8
(C-2), 118.5 (C-8), 120.8 (C-20/C-60), 123.8 (C-6), 124.4 (C-30/C-50),
124.5 (C-4a), 128.3 (C-5), 128.7 (C-7), 142.0 (C-40), 146.2 (C-10), 153.6
(C-8a), 180.6 (NHCSNH). Anal. (C16H14ClN3O3S) theoretical:




The title compound was obtained as described for 6a, starting
from 15 (0.15 g, 0.82 mmol) and 3-nitrophenyl isothiocyanate
(0.18 g, 1 mmol) (0.19 g, 64%): mp 178e180 C; 1H NMR (DMSO-d6)
d 2.06e2.24 (m, 2H, 3-H2), 4.25 (m, 2H, 2-H2), 5.66 (m, 1H, 4-H),
6.85 (d, J¼ 8.7 Hz,1H, 8-H), 7.23 (dd, J¼ 8.7 Hz/2.6 Hz,1H, 7-H), 7.32
(d, J ¼ 2.6 Hz, 1H, 5-H), 7.59 (t, J ¼ 8.1 Hz, 1H, 50-H), 7.85 (d,
J ¼ 8.1 Hz, 1H, 60-H), 7.94 (d, J ¼ 8.1 Hz, 1H, 40-H), 8.64 (bs, 2H, 20-H/
CH2NH), 9.9 (bs, 1H, NO2C6H4NH); 13C NMR (DMSO-d6) d 27.5 (C-3),
47.4 (C-4), 63.9 (C-2), 116.7 (C-20), 118.3 (C-40), 118.5 (C-8), 123.8 (C-
6), 124.8 (C-4a), 128.2 (C-5), 128.7 (C-7), 128.8 (C-60), 129.7 (C-50),
140.8 (C-10), 147.5 (C-30), 153.5 (C-8a), 180.4 (NHCSNH). Anal.
(C16H14ClN3O3S) theoretical: C, 52.82; H, 3.88; N, 11.55; S, 8.81.
Found: C, 52.63; H, 3.88; N, 11.55; S: 8.00.
5.2. Pharmacology
5.2.1. Determination of in vitro growth inhibitory activity in human
glioma cell lines
Wehavemadeuseof threehumangliomacell lines (Hs683,U373,
T98G) and one mouse melanoma cell line (B16F10 that can develop
as brain pseudometastases [31]). The U373 astroglioma cell linewas
obtained from the European Collection of Cell Culture (ECACC; code
96062201) and the remaining three cell lines from the American
Type Culture Collection (ATCC), i.e. the T98G astroglioma cell line
(code CRL-1690), the Hs683 oligodendroglioma (codeHTB-138) and
the mouse B16F10 melanoma (code CRL-6475) cell lines.
The inﬂuence of each compound under study on the in vitro
growth rates of the three human glioma cell lines, and on some
occasion of the mouse B16F10 melanoma, was determined using
the colorimetric MTT (3-[4,5-dimethylthiazol-2yl])-diphenyl
tetrazolium bromide, (Sigma, Belgium) assay as detailed previously
[13,29,31]. The use of the MTT colorimetric assay is based on the
capability of living cells to reduce the yellow product MTT (3-(4,5)-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to a blue
product, formazan, by a reduction reaction occurring in the mito-
chondria. The number of living cells after 72 h of culture in the
presence (or absence: control) of the various compounds is directly
proportional to the intensity of the blue, which is quantitatively
measured by spectrophotometry (Biorad Model 680XR; Biorad,
Nazareth, Belgium) at a 570 nm wavelength (with a reference of
630 nm). Each experiment was carried out in six replicates.
The cell lines were incubated for 24 h in 96-microwell plates (at
a concentration of 10,000e40,000 cells/mL culture medium
depending on the cell type) to ensure adequate plating prior to cell
growth determination. The cells were cultured in RPMI (Invitrogen,
Merelbeke, Belgium) media supplemented with 10% heat inacti-
vated fetal calf serum (Invitrogen). All culture media were sup-
plemented with 4 mM glutamine, 100 mg/mL gentamicin, and
penicillin-streptomycin (200 U/mL and 200 mg/mL) (Invitrogen).
5.2.2. In vitro growth inhibition analyses in normal astrocytes
Astrocyte culture. Astrocytes were obtained from neonatal NMRI
mouse cortices that were freed of meninges, minced into small
pieces of tissue with microscissors and then suspended in MEM
(Invitrogen) supplemented with glucose 6 g/L and 10% Fetal CalfSerum (FCS) (Invitrogen) and successively ﬁltered through
a 225 mm-pore and a 25 mm-pore ﬁlter. The ﬁltered cell suspension
was plated on an uncoated T25 ﬂask for 72 h. Themediumwas then
changed and cells were grown until conﬂuence.
MTTsurvivalassay. The day before the test of various compounds,
astrocytes are resuspended using a 0.25% trypsin/EDTA solution
and seeded in 96 wells plates (Nunc, Thermo Scientiﬁc, VWR,
Leuven, Belgium) at 30,000 cells/well density in 100 mL/well in the
serum-containing MEM except in column A (control wells for the
MTT assay). Various compounds are dissolved in a DMSO (dime-
thylsulfoxide) solution (SigmaeAldrich, Bornem, Belgium) at
a concentration that is 1000 of the ﬁnal dilution. A dose response
curve of the various tested solutions is set up in DMSO, allowing
adding in each culture well the DMSO solution at a ﬁnal concen-
tration 1/1000. Each dilution is tested in column of the 96 wells
plate or in octoplicates. A control column is set up by adding the
DMSO solution (1/1000 ﬁnal concentration) without any
compound. After 72 h of culture, culture medium is replaced by
a 50 mL MTT solution prepared at 0.15 mg/mL in MEM. MTT or (3-
(4,5-dimethylyhiazol-2-yl)-2,5-diphenyl tetrazolium bromide)
(SigmaeAldrich) was previously prepared as a 1.5 mg/mL stock
solution in MEM, then passed on a 0.22 mm ﬁlter and aliquoted
at 20 C. The plates are then cultivated for 3 h at 37 C. Then the
medium is discarded, cells are washed with a sterile PBS solution
and then 50 mL of an acidic isopropanol solution was added (20 mL
isopropanol supplemented with 120 mL of 37 M HCl). The plates are
read using a spectrophotometer using a 570 nm wavelength OD
(with a reference of 630 nm).
5.2.3. Computer-assisted phase-contrast videomicroscopy (quantitative
videomicroscopy)
As whether various compounds under study induced cytotoxic
versus cytostatic effects on U373 glioma cells were characterized
in vitrowith computer-assisted phase-contrast videomicroscopy as
described previously [27,30]. Cells were monitored for 72 h with
one image digitized every 4min andmovies were constructed from
the 1080 time-lapse image sequences, which enabled rapid
screening for cell viability.
5.2.4. Cell cycle analysis by ﬂow cytometry
Propidium iodide (PI; SigmaeAldrich) was used for cell cycle
analysis. Brieﬂy, cells were trypsinized and ﬁxed with 70% ethanol
overnight at 20 C, then pelleted before resuspending in PBS
containing PI (50 mg/mL; Invitrogen), RNAse A (0.1 mg/mL;
SigmaeAldrich) and Triton X-100 (0.05%; SigmaeAldrich) followed
by cytoﬂuorometric analysis with a FACSCalibur (Becton Dickinson,
Erembodegem, Belgium).
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